Lipid lowering therapy for acute coronary syndrome and coronary artery disease: Highlights of the 2017 Taiwan lipid guidelines for high risk patients

Yi-Heng Li, Ting-Hsing Chao, Ping-Yen Liu, Kwo Chang Ueng, Hung I. Yeh

研究成果: Review article

3 引文 (Scopus)

摘要

Intensive lipid lowering therapy is important in patients with acute coronary syndrome (ACS) and stable coronary artery disease (CAD). The 2017 Taiwan Lipid Guidelines for High Risk Patients was recently published. The guideline suggests that low-density lipoprotein cholesterol (LDL-C) should be the primary target, and that the treatment goal of LDL-C is < 70 mg/dL for patients with ACS or stable CAD. A lower target of < 55 mg/dL is appropriate for patients with ACS and diabetes mellitus. Non-high-density lipoprotein cholesterol (non-HDL-C) < 100 mg/dL can be considered as the secondary target after achieving the LDL-C goal for patients with a triglyceride level > 200mg/dL. Statins are usually the first-line therapy. Moderate or high intensity statins are preferred, and up-titration to the highest recommended and tolerable dose to reach the target is necessary. Combination therapy with statins and other lipid-lowering drugs can also be considered. We hope the clinical outcomes of patients with ACS or CAD can be improved in Taiwan through the implementation of the guideline recommendations.

原文English
頁(從 - 到)371-378
頁數8
期刊Acta Cardiologica Sinica
34
發行號5
DOIs
出版狀態Published - 2018 九月 1

指紋

Acute Coronary Syndrome
Taiwan
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coronary Artery Disease
Guidelines
Lipids
LDL Cholesterol
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

引用此文

@article{562e022850a640e1bf1c19cb10a681ab,
title = "Lipid lowering therapy for acute coronary syndrome and coronary artery disease: Highlights of the 2017 Taiwan lipid guidelines for high risk patients",
abstract = "Intensive lipid lowering therapy is important in patients with acute coronary syndrome (ACS) and stable coronary artery disease (CAD). The 2017 Taiwan Lipid Guidelines for High Risk Patients was recently published. The guideline suggests that low-density lipoprotein cholesterol (LDL-C) should be the primary target, and that the treatment goal of LDL-C is < 70 mg/dL for patients with ACS or stable CAD. A lower target of < 55 mg/dL is appropriate for patients with ACS and diabetes mellitus. Non-high-density lipoprotein cholesterol (non-HDL-C) < 100 mg/dL can be considered as the secondary target after achieving the LDL-C goal for patients with a triglyceride level > 200mg/dL. Statins are usually the first-line therapy. Moderate or high intensity statins are preferred, and up-titration to the highest recommended and tolerable dose to reach the target is necessary. Combination therapy with statins and other lipid-lowering drugs can also be considered. We hope the clinical outcomes of patients with ACS or CAD can be improved in Taiwan through the implementation of the guideline recommendations.",
author = "Yi-Heng Li and Ting-Hsing Chao and Ping-Yen Liu and Ueng, {Kwo Chang} and Yeh, {Hung I.}",
year = "2018",
month = "9",
day = "1",
doi = "10.6515/ACS.201809_34(5).20180629A",
language = "English",
volume = "34",
pages = "371--378",
journal = "Acta Cardiologica Sinica",
issn = "1011-6842",
publisher = "Republic of China Society of Cardiology",
number = "5",

}

TY - JOUR

T1 - Lipid lowering therapy for acute coronary syndrome and coronary artery disease

T2 - Highlights of the 2017 Taiwan lipid guidelines for high risk patients

AU - Li, Yi-Heng

AU - Chao, Ting-Hsing

AU - Liu, Ping-Yen

AU - Ueng, Kwo Chang

AU - Yeh, Hung I.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Intensive lipid lowering therapy is important in patients with acute coronary syndrome (ACS) and stable coronary artery disease (CAD). The 2017 Taiwan Lipid Guidelines for High Risk Patients was recently published. The guideline suggests that low-density lipoprotein cholesterol (LDL-C) should be the primary target, and that the treatment goal of LDL-C is < 70 mg/dL for patients with ACS or stable CAD. A lower target of < 55 mg/dL is appropriate for patients with ACS and diabetes mellitus. Non-high-density lipoprotein cholesterol (non-HDL-C) < 100 mg/dL can be considered as the secondary target after achieving the LDL-C goal for patients with a triglyceride level > 200mg/dL. Statins are usually the first-line therapy. Moderate or high intensity statins are preferred, and up-titration to the highest recommended and tolerable dose to reach the target is necessary. Combination therapy with statins and other lipid-lowering drugs can also be considered. We hope the clinical outcomes of patients with ACS or CAD can be improved in Taiwan through the implementation of the guideline recommendations.

AB - Intensive lipid lowering therapy is important in patients with acute coronary syndrome (ACS) and stable coronary artery disease (CAD). The 2017 Taiwan Lipid Guidelines for High Risk Patients was recently published. The guideline suggests that low-density lipoprotein cholesterol (LDL-C) should be the primary target, and that the treatment goal of LDL-C is < 70 mg/dL for patients with ACS or stable CAD. A lower target of < 55 mg/dL is appropriate for patients with ACS and diabetes mellitus. Non-high-density lipoprotein cholesterol (non-HDL-C) < 100 mg/dL can be considered as the secondary target after achieving the LDL-C goal for patients with a triglyceride level > 200mg/dL. Statins are usually the first-line therapy. Moderate or high intensity statins are preferred, and up-titration to the highest recommended and tolerable dose to reach the target is necessary. Combination therapy with statins and other lipid-lowering drugs can also be considered. We hope the clinical outcomes of patients with ACS or CAD can be improved in Taiwan through the implementation of the guideline recommendations.

UR - http://www.scopus.com/inward/record.url?scp=85053909542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053909542&partnerID=8YFLogxK

U2 - 10.6515/ACS.201809_34(5).20180629A

DO - 10.6515/ACS.201809_34(5).20180629A

M3 - Review article

AN - SCOPUS:85053909542

VL - 34

SP - 371

EP - 378

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

SN - 1011-6842

IS - 5

ER -